Modafinil showed no clear difference in leaving the study early ‐ for any reason compared with placebo (moderate certainty).
It is very uncertain whether chlorpromazine changes leaving the study early ‐ for any reason compared with piperacetazine (very low certainty).
It is very uncertain whether non‐TFCBT changes leaving the study early due to any reason compared with waitlist/Usual Care (very low certainty).
It is very uncertain whether other therapies changes leaving the study early due to any reason compared with waitlist/Usual Care (very low certainty).
Quetiapine showed no clear difference in leaving the study early due to any reason compared with typical antipsychotics (moderate certainty).
HALOPERIDOL showed no clear difference in leaving the study early ‐ Due to any reason compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (low certainty).
RISPERIDONE DEPOT probably leads to lower leaving the study early: Any reason ‐ long term compared with ORAL QUETIAPINE (moderate certainty).
It is very uncertain whether RISPERIDONE DEPOT changes leaving the study early: Any reason ‐ long term compared with ORAL ARIPIPRAZOLE (very low certainty).
RISPERIDONE DEPOT may leads to higher leaving the study early: Any reason ‐ long term compared with ORAL OLANZAPINE (low certainty).
RISPERIDONE DEPOT showed no clear difference in leaving the study early: Any reason ‐ long term compared with GENERAL ORAL ANTIPSYCHOTICS (moderate certainty).
RISPERIDONE DEPOT showed no clear difference in leaving the study early: Any reason ‐ short term compared with ORAL RISPERIDONE (moderate certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ long term ‐ any reason compared with typical antipsychotics (moderate certainty).
The intervention showed no clear difference in leaving the study early: any reason (medium term) (low certainty).
CANNABIS REDUCTION: ANTIPSYCHOTIC 'A' showed no clear difference in leaving the study early: any reason ‐ medium term compared with ANTIPSYCHOTIC 'B' for (moderate certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ any reason compared with typical antipsychotics (low certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ any reason compared with atypical antipsychotics (low certainty).
RISPERIDONE DEPOT may leads to higher leaving the study early for any reason ‐ long term compared with TYPICAL DEPOT ANTIPSYCHOTICS (low certainty).
It is very uncertain whether levomepromazine changes leaving the study early ‐ medium term ‐ any reason compared with typical antipsychotics (very low certainty).
It is very uncertain whether aspirin plus antipsychotics changes leaving the study early: short‐term – for any reason compared with placebo plus antipsychotics (very low certainty).